Pharma's next cash cows could be specialized treatments

Pharmaceutical companies are shifting focus from blockbuster drugs to specialized, personalized treatments designed for individual genetic and lifestyle profiles as they brace for a significant drop in profits due to patent expirations. This strategic pivot could reshape the landscape of disease treatment and health system costs in the coming decades. With over $500 billion in potential revenue from brand-name drugs at stake from 2026 to 2032, the industry's future hinges on its ability to innovate and cater to niche markets.